-
Follow us on Twitter
-
Recent Posts
Topics
- asbestos
- automotive
- autonomous vehicles
- biosimilar
- consumer products
- CPSC
- cybersecurity
- damages
- FDA
- food
- guidance
- Internet of Things
- jury
- litigation
- medical
- medical devices
- mobile
- NHTSA
- pharmaceutical
- privacy
- products
- recalls
- Trials
- Trucking/transportation
- Uncategorized
- unmanned aircraft systems/"drones"
- verdicts
Seven Snell & Wilmer product liability attorneys recognized as leaders in Product Liability Litigation – Defendants by The Best Lawyers in America 2020
Snell & Wilmer recently announced that 143 of the firm’s attorneys were selected by their peers for inclusion in The Best Lawyers in America©. Of those attorneys, seven partners were recognized in the practice area of Product Liability Litigation – … Continue reading
Share this Article:
Snell & Wilmer Attorneys Publish Article on Medical Device Servicing and Remanufacturing
Denver partner Dan Wittenberg and associate Kelly Smith recently published an article, “Clarifying the Difference Between Medical Device Servicing and Remanufacturing,” in DRI’s For the Defense. The article explores the longstanding divide in the medical device industry between device manufacturers … Continue reading
Share this Article:
FDA Makes Gene Therapy Available for First Time in USA
Earlier this week, the FDA made gene therapy available for the first time in the United States. This decision, ushers in “a new approach to the treatment of cancer and other serious and life-threatening diseases” said the FDA. The product, … Continue reading
Share this Article:
Senate Confirms New FDA Commissioner
Dr. Scott Gottlieb was confirmed today as the new FDA Commissioner. Dr. Gottlieb has promised to put public health first and not do anything “that shakes the public’s confidence in the agency.” He is a former hospitalist who served in the … Continue reading
Share this Article:
One in, Two Out: Potential FDA Uncertainty for Medical Device and Pharmaceutical Companies
By Daniel S. Wittenberg, Co-Chair, Medical Device and Pharmaceutical Industry Group On January 30, 2017, President Trump signed an executive order requiring all governmental agencies to eliminate two regulations for every one issued. The Order, captioned “Reducing Regulation and Controlling … Continue reading
Share this Article:
Summary of FDA Draft Guidance: Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions
By Daniel S. Wittenberg and Tim Scalo On June 16, 2016, the Food and Drug Administration (FDA) released a draft guidance entitled Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions. The non-binding draft guidance … Continue reading
Share this Article:
FDA Approves Second Biosimilar – Inflectra™ – The First Monoclonal Antibody Biosimilar
The U.S. Food and Drug Administration announced on April 5 its second ever approval of a biosimilar – Inflectra (infliximab-dyyb) – for multiple indications. Inflectra was developed by Celltrion Inc. and licensed to Pfizer Inc., for treatment of rheumatoid arthritis, … Continue reading
Share this Article:
Arizona Supreme Court Poised to Consider “Learned Intermediary” Doctrine
The Arizona Supreme Court has agreed to hear an appeal of the Court of Appeals’ January 2015 decision regarding the longstanding “learned intermediary” doctrine. In January, the lower court held that the doctrine was inconsistent with Arizona’s system of pure … Continue reading
Share this Article:
FDA Issues Unprecedented Alert Over Medical Device Cyber Security Risk
A fictional cyber-terrorist weaponizing a medical device by hacking into it has become a familiar plot premise in recent Hollywood dramas. Unfortunately, the risk of harm from medical device hacking has now become an actionable, real-world concern. In an unprecedented move, on July … Continue reading
Share this Article:
FDA Issues Final Guidance on Intent to Exempt Certain Medical Devices from Premarket Notification Requirements
On July 1, 2015 the FDA issued its final guidance regarding the intent to exempt certain unclassified medical devices, certain Class II medical devices, and certain Class I medical devices that are subject to the reserved criteria of section 510(l) … Continue reading
Share this Article: